Dr. Melissa Reed -- Pharmaceutical Payment Report
This page provides a comprehensive transparency report for Dr. Melissa Reed, a Endocrinology physician based in City, MD. All payment data is sourced from the CMS Open Payments (Sunshine Act) database. Dr. Melissa Reed has received $15,772.34 in total pharmaceutical industry payments across 1 transactions from 1 pharmaceutical companies.
Physician Profile
The following profile information is sourced from the National Provider Identifier (NPI) registry and CMS Open Payments records.
- Full Name: Dr. Melissa Reed
- Medical Specialty: Endocrinology
- Practice Location: City, MD, Maryland
- NPI Number: 1756162489
- Transparency Score: 100/100
- Payment Records Span: 2024-09-25 to 2024-09-25
Payment Summary
Dr. Melissa Reed has received a total of $15,772.34 in pharmaceutical industry payments across 1 recorded transactions in the CMS Open Payments database. The average payment amount is $15,772.34 per transaction.
- Total Payments Received: $15,772.34
- Number of Transactions: 1
- Average Payment: $15,772.34
- Transparency Score: 100/100 -- This score reflects the overall payment profile relative to peers in Endocrinology. A higher score indicates fewer or more routine payments.
- Number of Pharma Relationships: 1 pharmaceutical companies
- Drugs/Devices Referenced: 1 distinct products
Payment Breakdown by Category
The following table shows how Dr. Melissa Reed's pharmaceutical payments break down by payment category. Understanding the mix of payment types provides important context about the nature of the doctor-pharma relationship.
| Payment Category | Amount | Description |
|---|---|---|
| Consulting Fees | $15,772.34 | Advisory board participation, clinical consulting, and expert opinion services |
The largest payment category for Dr. Melissa Reed is Consulting Fees, accounting for 100% ($15,772.34) of total pharmaceutical payments received. This suggests active involvement in pharmaceutical company advisory and educational programs.
Pharmaceutical Company Relationships
The following pharmaceutical and medical device companies have made payments to Dr. Melissa Reed. Click on any company name to view their full physician payment profile and spending patterns.
| Company | Total Paid | Transactions |
|---|---|---|
| AstraZeneca | $15,772.34 | 1 |
Dr. Melissa Reed has a financial relationship with AstraZeneca, receiving $15,772.34 in total. Having a single pharmaceutical company relationship means all payments come from one source, which may indicate a focused consulting or research relationship.
Drugs and Medical Devices Referenced in Payments
The following drugs and medical devices have been referenced in pharmaceutical payments to Dr. Melissa Reed. These references indicate that the payment was related to the marketing, consulting, or clinical use of these products.
- Rybelsus -- Referenced in payment records from pharmaceutical companies to Dr. Melissa Reed
The presence of a drug or device in a payment record means the pharmaceutical company associated the payment with that product. This is common for consulting fees related to a specific medication, speaking engagements about a product, or research involving a particular drug or device.
AI Transparency Analysis
The following analysis was generated by artificial intelligence based on Dr. Melissa Reed's payment history, specialty peer comparisons, and payment pattern analysis. This analysis is not medical or legal advice.
Melissa Reed has received $15.8K across 1 pharmaceutical payments as a Endocrinology physician in City, MD. Top paying companies include AstraZeneca ($15.8K). Dr. Reed received a single payment of $15,772 in 2024, indicating a significant engagement with the pharmaceutical industry in that year. The entire payment originated from AstraZeneca, suggesting a strong, focused relationship with this specific company. This payment was categorized as 'consulting,' implying a role beyond simple product promotion.
Patient Guidance: Questions to Ask Your Doctor
If Dr. Melissa Reed is your physician, here is practical guidance on how to understand and discuss pharmaceutical industry relationships:
Patients should feel comfortable discussing any medications or treatments with their doctor, understanding that relationships with pharmaceutical companies can exist but should not compromise medical judgment. Always feel free to ask your doctor directly about their pharmaceutical relationships.
Peer Comparison: How Dr. Melissa Reed Compares to Other Endocrinology Physicians
Compared to other Endocrinologists, Dr. Reed's single, large payment from AstraZeneca is an outlier, as most physicians in this specialty have more diversified payment profiles.
Recent Payment Records
The following table shows the most recent pharmaceutical industry payments recorded for Dr. Melissa Reed in the CMS Open Payments database. Click on any payment to view the full report.
| Company | Amount | Type | Drug/Device | Date | Conflict Level |
|---|---|---|---|---|---|
| AstraZeneca | $15,772.34 | consulting | Rybelsus | 2024-09-25 | Not Assessed |
Frequently Asked Questions About Dr. Melissa Reed's Pharma Payments
Below are common questions patients ask about physician pharmaceutical payment data.
How much pharma money has Melissa Reed received?
Melissa Reed has received a total of $15.8K across 1 payments from pharmaceutical companies. This data is publicly reported under the CMS Open Payments (Sunshine Act) program.
Is Melissa Reed taking too much pharma money?
Melissa Reed has received $15.8K in pharmaceutical payments. Whether this is "too much" depends on the physician's specialty (Endocrinology), the types of payments, and how they compare to peers. The largest payment category is consulting ($15.8K). Payment does not imply wrongdoing, but patients should be aware and can ask their doctor directly.
What pharma companies pay Melissa Reed?
The top pharmaceutical companies paying Melissa Reed are: AstraZeneca ($15.8K). These payments cover various categories including consulting, meals, speaking fees, and research grants.
What kinds of payments does Melissa Reed receive?
Melissa Reed's payments by type: consulting: $15.8K. Consulting fees suggest active advisory roles with pharmaceutical companies.
Should I switch doctors because of pharma payments?
Pharma payments alone are not typically reason to switch doctors. Many payments are routine (like meals at educational events) and do not indicate compromised care. Focus on: (1) whether your doctor explains treatment options clearly, (2) whether generic alternatives are discussed, (3) the overall pattern of payments, not individual transactions. If you have concerns, ask your doctor directly.
How do Melissa Reed's payments compare to other Endocrinology doctors?
To compare, look at the total amount ($15.8K), number of payments (1), and the types of payments received. Endocrinology physicians may receive different payment amounts depending on subspecialty, geographic location, and academic affiliation. Use CMS Open Payments data to compare across the specialty.
How can I verify Melissa Reed's payment data?
You can verify this data directly through the CMS Open Payments database at openpaymentsdata.cms.gov. Search by physician name or NPI number (1756162489). All data is reported by pharmaceutical companies and verified by CMS. DoctorPharmaData aggregates this public data for easier access.
Do pharma payments affect prescribing quality?
Research published in JAMA Internal Medicine and other peer-reviewed journals shows a statistical association between pharmaceutical payments and prescribing patterns. However, correlation does not equal causation. Many physician-industry interactions are legitimate (research, education, advisory boards). The Sunshine Act was created to promote transparency so patients can make informed decisions.
What stands out about Melissa Reed's pharma payment profile?
The doctor's payment profile is highly concentrated with 100% of the total amount coming from a single company (AstraZeneca). Melissa Reed has received $15.8K in total pharma payments.
How does Melissa Reed compare to peers in Endocrinology?
Compared to other Endocrinologists, Dr. Reed's single, large payment from AstraZeneca is an outlier, as most physicians in this specialty have more diversified payment profiles.
Are Melissa Reed's pharma relationships typical for Endocrinology?
The single payment received is substantial, making up the entirety of the reported compensation.
What should patients of Melissa Reed know about these payments?
Patients should feel comfortable discussing any medications or treatments with their doctor, understanding that relationships with pharmaceutical companies can exist but should not compromise medical judgment.
What patterns are visible in Melissa Reed's payment history?
The payment is linked to a specific drug, Rybelsus, suggesting involvement in its promotion or research.
Understanding This Doctor Payment Report
This transparency report for Dr. Melissa Reed is based on data from the CMS Open Payments database, which is maintained by the Centers for Medicare and Medicaid Services under the Physician Payments Sunshine Act. Here are important things to understand:
- Payment does not imply wrongdoing. Many pharmaceutical payments represent legitimate professional activities such as consulting on drug development, speaking at medical education events, and conducting clinical research.
- Context matters. A large payment for conducting a clinical trial has very different implications than a large payment for promotional speaking. The payment breakdown by category above provides this context.
- Peer comparison is important. Whether a payment amount is unusual depends heavily on the physician's specialty, geographic location, and career stage. Endocrinology physicians may have very different payment norms than physicians in other fields.
- Data may be incomplete. The CMS Open Payments database captures payments from pharmaceutical and medical device manufacturers. It does not include payments from other sources, such as hospitals, insurance companies, or government agencies.
- Reporting thresholds apply. Small payments below certain thresholds may not be individually reported. The totals reflect payments above reporting minimums set by CMS regulations.
About the Physician Payments Sunshine Act
The Physician Payments Sunshine Act, enacted as Section 6002 of the Affordable Care Act in 2010, requires pharmaceutical and medical device companies to report payments and other transfers of value to physicians and teaching hospitals to CMS. This law was designed to increase transparency in the financial relationships between the healthcare industry and medical providers.
Under this law, Dr. Melissa Reed's pharmaceutical payments are publicly disclosed. The types of reportable transactions include consulting fees, compensated speaking or educational activities, honoraria, gifts, entertainment, food and beverages, travel and lodging, education or conference attendance, research grants, charitable contributions, royalties or licenses, current or prospective ownership interests, and direct compensation for services other than consulting.
The Open Payments data for Dr. Melissa Reed and all other physicians can be accessed at the official CMS Open Payments website.
Related Resources
- Endocrinology Specialty Payment Data -- See payment patterns for all endocrinology physicians
- Maryland Physician Payments -- Browse pharmaceutical payments to physicians in Maryland
- Endocrinology Physicians in Maryland -- Compare Dr. Melissa Reed to peers in the same state and specialty
- AstraZeneca Payment Profile -- View all payments made by Dr. Melissa Reed's largest pharmaceutical partner
- Search for Another Doctor or Company -- Look up any physician or pharmaceutical company in our database
- Official CMS Open Payments Database -- Verify payment data directly with the federal government
- NPI Registry -- Look up Dr. Melissa Reed's NPI (1756162489) in the official provider registry
Data from CMS Open Payments (Sunshine Act). Payment does not imply wrongdoing. AI analysis is not medical or legal advice. Consult your healthcare provider about any concerns.